Human papillomavirus (HPV) infection, cervical cancer and vaccination against HPV: a Nordic perspective

References

• Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24(suppl 3)S11–S25
   Web of Science ®Google Scholar
• Nordcan; Available online at: www.ancr.nu/nordcan.asp.
   Google Scholar
• Nohr B, Tabor A, Frederiksen K, Kjaer SK. Loop electrosurgical excision of the cervix and the subsequent risk of preterm delivery. Acta Obstet Gynecol Scand. 2007; 86: 596–603
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Bosch XF, Kummer JA, Shah KV. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12–9
   PubMed Web of Science ®Google Scholar
• Burchell AN, Winer RL, de Sanjosé R, Franco EL. Chapter 6. Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006; 24(suppl 3)S52–61
   Web of Science ®Google Scholar
• Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006; 24(Suppl 1)4–15
   Web of Science ®Google Scholar
• Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5. Updating the natural history of HPV and anogenital cancer. Vaccine. 2006; 24(suppl 3)S42–51
   Web of Science ®Google Scholar
• Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005; 337(1)76–84
   PubMed Web of Science ®Google Scholar
• Schiffman M ,Castle PE ,Jeronimo J ,Rodriguez AC ,Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890–907.
   PubMed Web of Science ®Google Scholar
• Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121: 621–32
   PubMed Web of Science ®Google Scholar
• Muñoz N, Castellsagué de Gonzáles AB, Gissman L. Chapter 1. HPV in the etiology of human cancer. Vaccine. 2006; 24(suppl 3)1–10
   PubMed Web of Science ®Google Scholar
• Schiller JT, Lowy DR. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res. 2006; 66: 10229–32
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with pre-existing infection. JAMA. 2007; 298: 743–53
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Harper DM. Current findings from prophylactic vaccine trials. Vaccine. 2006; 24(suppl 3)114–21
   Web of Science ®Google Scholar
• The Future II Study Group . Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1928–43.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romonowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4–5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 1247–55
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19)1928–43
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvant bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369(9580)2161–70
   PubMed Web of Science ®Google Scholar
• Elmar AJ, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) virus-like particle vaccine against high-grade vulvar and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007; 369: 1693–702
   PubMed Web of Science ®Google Scholar
• Crosbie EJ, Kitchener HC, Cervarix TM. A bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer. Expert Opin Biol Ther. 2007; 7: 391–6
   PubMed Web of Science ®Google Scholar
• Goldie S, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected benefits of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604–15
   PubMed Web of Science ®Google Scholar
• Kjær SK, Hogdall E, Frederiksen K, Munk C, van den Brule AJC, Svare E, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus positive, cytologically normal women over a 10-year period. Cancer Res. 2006; 66: 10630–6
   PubMed Web of Science ®Google Scholar
• Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 97: 1072–9
   PubMed Web of Science ®Google Scholar
• Vaksiner mot humant papillomavirus (HPV) . Vurdering av effekt av profylaktiske HPV-vaksiner Rapport fra Kunnskapssenteret Nr 5–2007, Medisinsk metodevurdering.
   Google Scholar
• National Board of Health. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) – a health technology assessment. Copenhagen: Danish Centre for Health Technology Assessment. Available online at:, , http://www.sst.dk/publ/Publ2007/MTV/HPV/HPV_vaccination_en.pdf.
   Google Scholar
• Dillner J ,Andrea B ,Westermark B. Svensk konsensus om vaccination mot cervixcancer. Läkartidningen. 2006;103:3377–9. English summary availabe online at: http://Itarkiv.lakartidningen.se.
   Google Scholar